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DNA-bindingThe Epstein–Barr virus (EBV) growth-transforms B-lymphocytes. The virus-encoded nuclear antigen 2
(EBNA2) is essential for transformation and activates gene expression by association with DNA-bound
transcription factors such as RBPJκ (CSL/CBF1). We have previously shown that EBNA2 contains
symmetrically dimethylated Arginine (sDMA) residues. Deletion of the RG-repeat results in a reduced
ability of the virus to immortalise B-cells. We now show that the RG repeat also contains asymmetrically
dimethylated Arginines (aDMA) but neither non-methylated (NMA) Arginines nor citrulline residues. We
demonstrate that only aDMA-containing EBNA2 is found in a complex with DNA-bound RBPJκ in vitro and
preferentially associates with the EBNA2-responsive EBV C, LMP1 and LMP2A promoters in vivo. Inhibition of
methylation in EBV-infected cells results in reduced expression of the EBNA2-regulated viral gene LMP1,
providing additional evidence that methylation is a prerequisite for DNA-binding by EBNA2 via association
with the transcription factor RBPJκ.
© 2009 Elsevier Inc. All rights reserved.Introduction
The Epstein–Barr virus (EBV) is associated with various human
malignancies and readily growth-transforms primary human B-
lymphocytes generating lymphoblastoid cell-lines, the in vitro
correlate of the tumour cells of EBV-associated post-transplant
lymphoproliferative disease (PTLD) (for review, see Rickinson and
Kieff, 2007). In EBV-transformed lymphocytes, 11 so-called latent
genes are expressed. Of these, only the nuclear antigens EBNA-1, -2,
-3a, -3c and the latent membrane protein LMP1 are necessary for
transformation (reviewed in Bornkamm and Hammerschmidt, 2001).
EBNA2 is a multifunctional transcriptional activator (for a recent
review, see Palermo et al., 2008). Although it self-associates (Harada
et al., 2001), a property often observed for DNA-bound transcription
factors, it does not bind directly to DNA but is tethered to promoter
elements by interacting with DNA-bound cellular transcription fac-
tors. For example, it associates through its Trp-Trp-Pro (“WWP325”)ll rights reserved.motif at positions 323–325 with the DNA-bound repressor RBPJκ
(Henkel et al., 1994; Ling and Hayward, 1995; Zimber Strobl et al.,
1993) thereby converting RBPJκ to the transcriptionally active form in
an analogous fashion to the cellular transmembrane receptor, Notch
(reviewed in Zimber Strobl and Strobl, 2001). A virus encoding an
EBNA2 protein with a mutation in the WWP-motif is unable to
immortalise B-lymphocytes and does not activate the viral oncogene
LMP1 (Cohen, Wang, and Kieff, 1991). EBNA2 binds to a variety of
basal transcription factors (Bornkamm and Hammerschmidt, 2001)
and also forms complexes with proteins involved in RNA metabolism
like the DEAD-box protein DDX20 (DP103/Gemin3) (Grundhoff et al.,
1999) or the survival of motor neurons (SMN) protein (Barth et al.,
2003; Voss et al., 2001). The binding of EBNA2 to a variety of other
host proteins is reﬂected by its presence in high molecular weight
complexes of different composition (Grässer et al., 1991; Tsui and
Schubach, 1994; Wu et al., 2000). In mitotic cells, the transcriptional
activity of EBNA2 is inhibited through phosphorylation at Serine 243
(Yue et al., 2005; Yue et al., 2006). Fig. 1 shows a schematic
representation of EBNA2.
EBNA2 features an Arginine–Glycine (RG-) repeat element at
positions 339–354 which contains symmetrically dimethylated
Fig. 1. Schematic representation of the Epstein–Barr virus nuclear antigen 2 (EBNA2).
EBNA2 of the standard B95.8 strain (accession number: AJ507799) of EBV consists of
487 amino acids (aa) present in a A-type viruses. The N-terminal dimerisation domain
(“Dim”) is located next to a poly-proline stretch (“Pro”). The variable region
(“variable”) differs between the A-type viruses and B-type viruses. B-type viruses
have a reduced in vitro transformation potential. The binding site for RBPJκ (“RBPJκ”) is
located around a Trp-Trp-Pro motif at aa 323–325. The adjacent Arginine–Glycine
repeat (“ArgGly”) between aa 339 and 354 confers binding to the survival of motor
neurons (SMN) protein and represents the second nuclear localisation signal (“NLS”) in
addition to the canonical NLS found at the extreme C-terminus between aa 468 and 487.
The C-terminal acidic transactivation domain (“TAD”) between aa 424 and 468
interacts with various basal transcription factors.
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of the survival motor neuron protein (SMN) (Barth et al., 2003). EBNA2
might therefore represent the viral counterpart of the cellular SmD3
protein, which also associates with the Tudor domain of SMN via a
symmetrically dimethylated RG repeat (Friesen and Dreyfuss, 2000).
The deletion of the RG-repeat of EBNA2 results in a protein with a ﬁve-
fold higher ability to stimulate expression of the viral oncogene LMP1
in reporter assays, but a recombinant virus featuring this deletion in
EBNA2 has reduced transforming activity and needs an extended time
span to induce transformed cell clones (Tong et al., 1994).
Methylation is a posttranslational modiﬁcation that affects protein–
protein interactions (Gary and Clarke, 1998) and plays a role in signal
transduction, cellular proliferation, transcriptional processing and spli-
cing of mRNA (Azzouz et al., 2005; Kim et al., 1997; Lee et al., 2005;Fig. 2. Detection of methylated EBNA2 species. (A) Monoclonal antibodies (mAbs) directed
Glycine (RG)-repeat of EBNA2 were tested by precipitation using extracts of EBV-positive
exclude unspeciﬁc binding to the protein G sepharose. Precipitated EBNA2 protein was visu
(B) Immunoprecipitation of EBNA2 from transiently transfected cells. HEK 293-T cells exp
various methylation speciﬁc monoclonal antibodies as indicated using appropriate isotype co
of aDMA-antibody by aDMA peptide. The aDMA-speciﬁc antibody 6F12 was used in a Weste
Speciﬁc inhibition of sDMA-antibody by sDMA peptide. Extract of B95.8 cells was used for im
sDMA peptide. Irrelevant control antibody was used as an internal control. Precipitated EBNStallcup et al., 2003). In addition to Lysine residues, methylation on
proteins also takes place at Arginines (Paik and Kim, 1967) which leads
to three known forms in higher eukaryotes: ω-NG-MonoMethyl-Argi-
nine (MMA), ω-NG,NG-asymmetric DiMethyl-Arginine (aDMA) and ω-
NG,N′G-symmetric DiMethyl-Arginine (sDMA); the methylation of the
internal guanidino nitrogen atom to form δ-NG-MonoMethylArginine
has only been detected so far in yeast (for a recent review, see Bedford
and Clarke, 2009). The methylation reactions are catalyzed by Protein-
Arginine-Methyl-Transferases (PRMTs), which can be classiﬁed as type I
enzymes (PRMT-1, -2, -3, -4, -6) which generate aDMA and type II
enzymes (PRMT5, -7) which generate sDMA (for review, see Bedford
and Richard, 2005). So far, JmjD6 is the only Arginine-demethylating
enzyme with a demonstrated activity towards histone H3R2 and his-
tone H4R3 (Chang et al., 2007). In addition, MMA- and aDMA-modiﬁed
Arginines may be deiminated by the enzyme PADI4 to form citrulline
residues (Cuthbert et al., 2004; Wang et al., 2004). Here we show using
newly developed monoclonal antibodies (mAbs) that sDMA- and
aDMA- but not NMA- nor citrulline-containing EBNA2 is present in
EBV-infected cells. Most importantly, we demonstrate that asymmetri-
cally Arginine dimethylated EBNA2 preferentially associates with DNA-
bound RBPJκ in vitro and with EBNA2-responsive promoters in vivo.
Results
EBNA2 contains either symmetrically or asymmetrically dimethylated
residues within its Arginine–Glycine (RG-) repeat
We had previously shown that the RG-repeat of EBNA2 contains
sDMA-modiﬁed residues (Barth et al., 2003). To test whether EBNA2
also contains aDMA-modiﬁed, non-methylated Arginines or citrullineagainst the non-methylated (NMA), sDMA-, aDMA-, or citrulline containing Arginine–
B95.8 cells. For each antibody, an appropriate isotype control was tested in parallel to
alised using the EBNA2-speciﬁc mAb R3 which binds outside the RG-domain of EBNA2.
ressing either EBNA2-wt or the EBNA2-RG mutant were precipitated with R3 and the
ntrol antibodies. The position of EBNA2 is indicated by an arrow. (C) Speciﬁc inhibition
rn blot either untreated or pre-incubated with aDMA or sDMA-peptide as indicated. (D)
munoprecipitation using either untreated or antibody 7D9 preincubated with aDMA or
A2 was detected by Western blot using the R3 antibody.
301H. Gross et al. / Virology 397 (2010) 299–310residues instead of Arginines, we generated mouse or rat monoclonal
antibodies (mAbs) against the various possible variations in its RG-
repeat. KLH-coupled peptides corresponding to the non-methylated,
symmetrically or asymmetrically dimethylated RG-repeat of EBNA2
or a peptide containing citrulline instead of Arginine residues were
used for the immunisation, while the same peptides bound to OVA
were then used in an ELISA screening assay (see Table S1, supple-
mentary data). Only those antibodies that reacted exclusively with
their cognate peptidewere established as stable clones. The speciﬁcity
of the antibodies was conﬁrmed in a dot-blot assay (Figure S1,
supplementary data). The antibodies were then tested by immuno-
precipitation using extracts of EBV-positive B95.8 cells. The pre-
cipitated EBNA2 was detected using the previously described anti-
body R3 that binds to a C-terminal epitope outside the RG-repeat
(Kremmer et al., 1995). As shown in Fig. 2A, only the sDMA and
aDMA-speciﬁc but not the NMA- or citrulline-speciﬁc antibodies
yielded a signal for EBNA2 indicating that both methylated forms are
present in EBV-infected cells. EBNA2 was then immunoprecipitated
from extracts of 293-T cells transiently expressing either EBNA2-wt or
the mutant EBNA2-ΔRG with a deletion of the RG repeat (Tong et al.,Fig. 3. (A) Inhibition of methylation by AdOx treatment. EBNA2 was precipitated with the in
Precipitated EBNA2 was visualised using the R3 antibody. The IgG heavy (“IgG-h”) and ligh
secondary peroxidase coupled anti-rat antibody. Co-electrophoresed molecular mass mark
albumin (BSA), ovalbumin (OVA), and carboanhydrase. (B) Only aDMA-EBNA2 is phosphor
labelled B95.8 cell extracts. The bound EBNA2 was analysed by SDS-PAGE and autoradiograp
marker proteins (× 10-3 Da) were, in descending order: phosphorylase B, bovine serum alb1994). As shown in Fig. 2B, the sDMA and aDMA-speciﬁc antibodies
reacted with EBNA2-wt but not the deletion mutant demonstrating
that the correct epitope on EBNA2 was recognised. Moreover, the
signal for EBNA2 could be inhibited by preincubation of the 6F12
antibody with the aDMA-containing peptide but not the sDMA-
peptide demonstrating again that the antibody is speciﬁc for aDMA-
EBNA2 (Fig. 2C). Vice versa, we were able to inhibit the immunopre-
cipitation of EBNA2 by the sDMA-speciﬁc antibody 13B10 using the
sDMA peptide but not the aDMA-peptide (Fig. 2D).
EBV-positive B95.8 cells were then treated with the methylation
inhibitor AdOx prior to immunoprecipitation of EBNA2. As can be
seen in Fig. 3A, the overall amount of EBNA2 remained essentially
unchanged while the signal obtained with the sDMA- or aDMA-
speciﬁc antibodies decreased. In addition, we now detect a signal for
EBNA2 with the NMA-speciﬁc antibody. We observed additional
immunoreactive bands above the EBNA2 signal which might be
derived from IgG molecules that contained incompletely reduced
disulﬁde bonds. The appearance of unmethylated EBNA2 in the
AdOx-treated cell extract conﬁrms the speciﬁcity of the NMA-
antibody. Our data demonstrate that EBNA2 does not exist in a non-dicated antibodies from B95.8 cell extract treated with the methylation inhibitor AdOx.
t (“IgG-l”) chains of the antibodies released from the beads were also detected by the
er proteins (× 10-3 kDa) were, in descending order: phosphorylase B, bovine serum
ylated. The different antibodies as indicated were used to precipitate EBNA2 from 32P-
hy. The position of EBNA2 is indicated. Co-electrophoresed 14C-labelled molecular mass
umin (BSA), ovalbumin (OVA), and carboanhydrase.
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converted to citrullines. Most importantly, the antibody 6F12 (see
below) developed against a peptide containing aDMA reacted with
EBNA2 indicating that a substantial fraction contains aDMA in
addition to the sDMA-modiﬁed EBNA2 establishing aDMA as a novel
modiﬁcation of EBNA2.We obtained comparable signals for sDMA- vs.
aDMA-containing EBNA2 but since the antibodies used may display
different afﬁnities for their antigens, this does not provide absolute
quantiﬁcation of the relative abundance of the two methylated forms.
Only ADMA-modiﬁed EBNA2 is phosphorylated
EBNA2 is a phosphoprotein (Grässer et al., 1992; Petti et al., 1990).
Hyperphosphorylationwas shown to inhibit transcriptional activation
of EBNA2 during mitosis (Yue et al., 2004). To test whether the aDMA-
or sDMA-modiﬁed EBNA2 are phosphorylated, EBV-positive B95.8 B-
cellsweremetabolically labelledwithH332PO4 and the cell extractwas
immunoprecipitated with the different antibodies and subsequently
analysed by SDS-PAGE and autoradiography (Grässer et al., 1991). As
can be seen in Fig. 3B, the precipitation with the aDMA-speciﬁc
antibody as well as the R3-antibody but not the sDMA-, NMA- or
citrulline-speciﬁc antibodies yielded signals for EBNA2. This data
indicates that only the aDMA-modiﬁed EBNA2 is detectably phos-
phorylated. We noticed additional bands co-precipitated by the
aDMA- and sDMA-speciﬁc antibodies. As EBNA2 formshigh-molecularFig. 4.Methylated EBNA2 is present in high molecular weight complexes. Native cell extract
either concentrated by ethanol precipitation and then analysed by Western blot analysis wit
byWestern blot analysis (panel labelled “IP/WB”) with the indicated antibodies. The GST-sp
bands at approx. 50 kDa represent the heavy chains of the antibodies used for precipitation th
marker proteins were described in Fig. 2.weight complexes, these phosphoproteins might represent factors
associated with either aDMA or sDMA-modiﬁed EBNA2. The bands
that were precipitated with the aDMA-speciﬁc antibody migrated to
different positions in the gel than those precipitated by the sDMA-
speciﬁc antibody indicating that the sDMA and aDMA forms of EBNA2
associate with different cellular proteins. We also tested whether the
induction of lytic EBV-replication by TPA inﬂuences the methylation
status of EBNA2 as it was shown that phosphorylation of Serine 243 by
the viral kinase BGLF4 was induced during lytic cycle replication (Yue
et al., 2005). The induction of the lytic cycle was conﬁrmed using
recently developed antibodies against the viral DNA polymerase
(Barth et al., 2008) or against the BZLF1 protein (Young et al., 1991).
We found no change in the methylation of the protein upon lytic cycle
induction by TPA-treatment (see supplemental Figure S2A), while the
AdOx-treatment reduced themethylation of EBNA2 but did not induce
the lytic cycle (see supplemental Figure S2B).
aDMA and sDMA-containing EBNA2 is detectable in high-molecular
weight complexes
EBNA2 forms high molecular weight complexes consistent with its
association with multiple proteins (Grässer et al., 1991; Wu et al.,
1996). Nuclear extracts were separated by 5–40% sucrose gradient
centrifugation (Grässer et al., 1991) and tested in aWestern blot using
the antibody R3 or the aDMA-speciﬁc clone 6F12. As shown in Fig. 4,s were subjected to 5–40% sucrose gradient centrifugation. The fractions obtained were
h the indicated antibodies (panels labelled “WB”) or subjected to precipitation followed
eciﬁc mAb 6G9 (Kremmer, unpublished) was used as a control for the precipitation. The
at are detected by the secondary peroxidase-coupled anti-rat antibody. Molecular mass
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representing dimeric EBNA2 in complexes of about 300–400 kDa. In
contrast, the aDMA-speciﬁc clone 6F12 yielded the strongest signal in
fractions 10–13 corresponding to a molecular mass of about 500–
700 kDa and a distinct signal in the bottom fraction 17 corresponding
to a very high molecular mass. Extreme care was taken to avoid
resuspending particulate material that might have sedimented at the
bottom of the centrifuge tubes. Tsui and Schubach (1994) have
described an EBNA2 species of 3–4 MDa detectable in gel ﬁltration
experiments which is consistent with the EBNA2 species present in
fraction 17. Using 6F12 (aDMA antibody), we also observed an
immunoreactive band of approx. 200 kDa in fractions 3–6 that might
represent dimeric EBNA2 as the samples were not boiled prior to the
gel electrophoresis. Because the sDMA-speciﬁc antibodies did not
work in Western blot analysis, we subjected the fractions of the
gradients to an immunoprecipitation employing EBNA2-R3, the
sDMA- or aDMA-speciﬁc antibodies and an irrelevant control
antibody. The precipitated EBNA2 was visualised using R3. As can be
seen in Fig. 4, the control antibody gave no signal, while the pre-
cipitationwith R3 and the other antibodies yielded signals with a peak
in fractions 3–6. R3 and the aDMA- and sDMA-speciﬁc mAbs also
precipitated higher molecular weight species (fraction 17). The major
part of aDMA-containing EBNA2 sediments in the fractions 10–13
corresponding to the higher molecular weight complexes while the
precipitation mainly yielded a signal in the fractions 3–6 for the lower
molecular mass complexes. This result indicates that the former
complexes contain proteins bound to the modiﬁed RG-repeat which
render this epitope inaccessible to the antibody by immunoprecipi-
tation. Because we clearly detect some EBNA2 precipitated from
fraction 17 presenting very high molecular weight complexes, we
assume that sDMA-containing EBNA2 is also present in the fractions
10–13 but cannot be precipitated because of RG-bound proteins.
Only aDMA-containing EBNA2 is detectable in DNA-binding complexes
in vitro
We next tested for the presence of methylated EBNA2 in DNA-
associated complexes. For this purpose, we analysed the ability of the
methylation-speciﬁc antibodies to induce a supershift in an electro-
phoretic mobility shift assay (EMSA). We had originally shown that
EBNA2 is tethered via RBPJκ to its cognate promoter sequences
(Zimber Strobl et al., 1993). It is important to point out that although
considerable evidence, including data from chromatin immunopre-
cipitation experiments (Bark-Jones, Webb and West, 2006), supports
the fact that EBNA2 stably associates with DNA via RBPJκ, we and
others have found that EBNA2 can destabilise the single RBPJκ-DNA
complex detected in gel retardation assays carried out using C
promoter probes containing one RBPJκ binding site (Waltzer et al.,
1994, 1996 and our unpublished data). It is therefore important to
ensure that the in vitro assays used accurately reﬂect the behaviour of
RBPJκ and EBNA2 in vivo. Using an LMP 2A/TP1 promoter probe
containing two RBPJκ sites allows the detection of the RBPJκ and/or
EBNA2-containing complexes: complex I represents one molecule of
RBPJκ bound to DNA, complex III corresponds to two molecules of
RBPJκ, and complex IV contains two molecules of RBPJκ and one
molecule of EBNA2, while cell proteins non-speciﬁcally bound to the
promoter are present in complex II. Complex IV can be “supershifted”
by R3 (Meitinger et al., 1994). Conversely, the interaction of EBNA2
with the DNA-bound RBPJκ can be destroyed by the antibody 6C8
which recognises the “WWP”-motif of EBNA2 necessary for binding to
RBPJκ (Sauder et al., 1996). Prior experiments had shown that EBNA2
generated in a reticulocyte-based system was able to induce an
EBNA2-speciﬁc shift that could be supershifted with R3 antibody and
was also destroyed by the 6C8 antibody as was observed for EBNA2
from native cell extracts (Meitinger et al., 1994; Sauder et al., 1994;
Zimber Strobl et al., 1993). In addition, cell extract as a source forRBPJκ can also be substituted by IVT-RBPJκ from the reticulocyte
system (Maier et al., 2005). The in vitro generated EBNA2 reacted with
the antibody 6F12 (aDMA) in aWestern blot andwas also precipitated
using the sDMA-speciﬁc antibody 7D9 indicating that both sDMA and
aDMA modiﬁed EBNA2 were generated (Figure S3, supplementary
data) in line with our previous report that the reticulocyte-based
EBNA2 contains sDMA residues (Barth et al., 2003). As can be seen in
Fig. 5A, EBNA2 alone did not bind to the probe (lane 2) while the IVT-
RBPJκ yielded a band (lane 3) that could be shifted with IVT-EBNA2
(lane 4) and could furthermore be supershifted by R3 (lane 5). The
WWP mAb 6C8 destroyed this complex (lane 6). Signiﬁcantly, only
the aDMA-speciﬁc clone generated a supershift (lane 11), while
neither the NMA-, the sDMA- nor the control antibodies bound to the
RBP-Jκ-EBNA2DNA bound complex (lanes 7–10). The same result was
also obtained when gel shift experiments were carried out using
extracts from EBV-infected cells (Fig. 5B). Here, the R3 antibody
supershifted complex IV (Fig. 5B, lane 4) which was destroyed by 6C8
(lane 5), while only the aDMA-speciﬁc antibody induced a supershift
(lane 10). Moreover, when reticulocyte-derived EBNA2 was used in
conjunction with cell extract derived from the EBNA2-deﬁcient, EBV-
positive P3HR1 cell line, we again obtained an EBNA2-speciﬁc band
that was only supershifted by R3 and the aDMA-speciﬁc clone 6F12,
but not by the sDMA- or NMA-speciﬁc antibodies (data not shown).
These data therefore support the notion that the aDMA-modiﬁcation
of EBNA2 is necessary to promote the association of EBNA2with DNA-
bound RBPJκ. To exclude the possibility that the gel shift buffer
conditions prevented binding of the sDMA-speciﬁc antibody to its
epitope, immunoprecipitations were carried out using the same
nuclear extracts and conditions. We could clearly precipitate EBNA2
with the sDMA-speciﬁc antibody (supplementary Figure S4A).
Furthermore, we found that the antibodies still bound to their OVA-
conjugated peptides in a dot-blot assay when the blot strips were
incubated with up to 2 M NaCl excluding grossly different binding
afﬁnities as an explanation for the observed results (data not shown).
Methylation is a prerequisite for interaction of EBNA2 with
DNA-bound RBPJκ
Next, we analysed nuclear extracts of cells treated or untreated
with the methylation inhibitor AdOx in a gel shift assay. We observed
a decrease inmethylation of EBNA2 in these extracts while the level of
the protein was unaffected (see above). As can be seen in Fig. 6A, the
EBNA2-derived shift observed with untreated cell extract was
stronger than the one obtained with the AdOx-treated extract
demonstrating again that methylation of EBNA2 inﬂuences its
interaction with DNA-bound RBPJκ. The determination of the signal
strength showed a decrease in signal intensity of 30–67% for the
AdOx-treated samples (compare, i.e., lanes 2 and 3). Again, we only
observed a supershift with R3 (lanes 6 and 7) and the aDMA-speciﬁc
antibody (lanes 18 and 19). Here, untreated extract showed a super-
shift with the aDMA antibody (lane 18) while essentially no supershift
with this antibody was detectable with the AdOx-treated sample
(lane 19). For better clarity, the upper part of the gel depicted in Fig.
6A as well as a quantiﬁcation of the signal from the supershift of the
treated and the corresponding untreated samples is shown in Fig. 6B.
Methylation converts non-binding EBNA2 into a DNA-associated form
We then assayed the DNA-binding properties of non-methylated
EBNA2 produced in an E. coli-based transcription–translation system
(“E. coli E2”). By precipitation with the NMA-speciﬁc antibody we
could show that the E. coli-based EBNA2 was indeed not methylated
and initial experiments indicated that the E. coli-EBNA2 did not bind
to DNA (data not shown). To determine whether methylation of
EBNA2 by a methyl transferase activity in the reticulocyte system
converted EBNA2 into the RBPJκ-associated, DNA-binding form, we
Fig. 5. aDMA-modiﬁed EBNA2 is present in DNA-binding complexes. (A) EBNA2 and RBPJκ synthesised in a coupled in vitro transcription–translation system derived from rabbit
reticulocytes (Promega) were used in a gel shift (EMSA) (Meitinger et al., 1994) after preincubation of the proteins with the indicated antibodies. The complexes III and IV which
are formed by RBPJk and RBPJκ plus EBNA2, respectively, as well as complex IV supershifted with mAb R3 (lane 4) or aDMA-speciﬁc mAb 6F12 (lane 11) are indicated. (B) EBNA2-
containing Raji cell extract was incubated with the indicated antibodies and then assayed in a gel shift assay. R3 recognises EBNA2 regardless of its methylation status and induces
a “supershift” indicated by the upper arrow (Zimber Strobl et al., 1993), the mAb 6C8 directed against the “WWP”-repeat of EBNA2 destroys the EBNA2/RBPJκ-complex IV (Sauder
et al., 1994). Antibodies used are indicated above each lane. Control antibodies corresponded to the respective IgG-subtype of each antibody. To efﬁciently separate the high
molecular weight complexes, the electrophoresis was carried out for an extended time. Therefore, uncomplexed 32P-labelled probe ran out of the gel. The position of the RBPJκ-
containing complexes I–IV as described in the text are indicated; the arrow points at the EBNA2-containing complex IV that is supershifted by R3 and aDMA-6F12 but destroyed
by WWP-6C8.
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based transcription–translation extract supplemented with the
methyl donor SAM and carried out the EMSA using this remethy-
lated-EBNA2 (“Rem. E2”) in conjunction with IVT RBPJκ. Gel shift
assays were carried out with the same amount of E. coli-EBNA2 as the
reticulocyte-EBNA2 (“Retic E2”) and IVT-RBPJκ. The E. coli-EBNA2, the
remethylated-EBNA2 or the reticulocyte-EBNA2 did not produce a
supershift alone (Fig. 6C, lanes 3, 4 and 5, respectively). The
remethylated and the reticulocyte EBNA2 were then either assayed
with control-antibody (lanes 6 and 7, respectively), R3 (lanes 8 and
9), the sDMA-speciﬁc antibody (lanes 10 and 11) or aDMA-speciﬁc
antibody (lanes 12 and 13). As can be seen, only R3 and the aDMA- but
not the sDMA-antibody induced a supershift. The NMA-speciﬁc
antibody also did not generate a supershift (Figure S5, supplementary
information). Western blot analysis (Fig. 6D) conﬁrmed that the
C-terminal antibody R3 recognised EBNA2 from both the reticulocyte-
and the E. coli-based IVT system while the aDMA-speciﬁc antibody
6F12 only reacted with the remethylated-EBNA2 but not the E. coli-
EBNA2 showing that aDMA-EBNA2 can be generated in vitro.
To determine whether demethylation of EBNA2 in vivo results in a
reduction in EBNA2-activated transcription of its target promoters, we
investigated the expression of the EBNA2-responsive LMP1 gene.
EBV-infected B95.8 monkey cells or the human IB4 lymphoblastoid
cell line immortalised with B95.8 virus were treated with AdOx.
Although the overall amount of EBNA2 was only reduced by 10–20%,
we observed a 70% reduction in the amount of aDMA-EBNA2 detected
by Western blot and a corresponding decrease in the expression ofLMP1 by 40–50% while the β-actin loading control was unaffected
(Fig. 7). Comparable results were obtained using Raji cells (data not
shown). These results support the notion that methylation is a
prerequisite for binding of EBNA2 to DNA.
aDMA modiﬁed EBNA2 preferentially binds to promoters in vivo
To investigate the effect of EBNA2 methylation on the binding of
EBNA2 to promoters in vivo, we carried out chromatin immunopre-
cipitation experiments using a matched pair of EBNA2 negative and
positive Burkitt's lymphoma cell-lines. The group I Burkitt's lympho-
ma (BL) cell-line Mutu I was derived from a tumour biopsy and
maintains the characteristic restricted form of latency (latency I)
found in BL, associated with the expression of only EBNA 1. The Mutu
III cell-line was derived fromMutu I cells that had drifted in culture to
express the full panel of EBV latent genes including EBNA2 (latency
III). These cell-lines therefore allow an examination of the transcrip-
tional effects of EBNA2 in the same cell background. The presence or
absence of EBNA2 in the two cell lines was conﬁrmed byWestern blot
analysis (supplemental Figure S6 and data not shown). Primers were
designed to amplify three EBNA2 target EBV promoters; the C pro-
moter (Cp), the LMP1 promoter (LMP1p) and the LMP2A promoters
(LMP2Ap) (Figs. 8A–C, respectively). Using the R3 antibody, we
observed the expected proﬁle of EBNA2 binding to Cp, peaking in the
region encompassing the RBPJκ site (-368 to -374, Waltzer et al.,
1994) detected by the -430 to -355 amplicon (-430) (Fig. 8D). These
results were in line with our previous observations using the anti-
Fig. 6. Methylation of EBNA2 is a prerequisite for DNA-binding. (A) Extracts of Raji cells either treated (lanes designated “+”) or untreated (lanes designated “−”) with the
methylation inhibitor AdOx were used in the gel shift experiments. The antibodies used are given above each lane. The upper arrow indicates the supershifted EBNA2-containing
complex IV. (B) The ﬁgure shows the quantiﬁcation upper section of the supershift shown in Fig. 5A together with the quantiﬁcation of the supershifted EBNA2-containing complex
obtained using the PhosphoImager® (GE Healthcare, Freiburg, Germany). (C) Remethylation generates DNA-binding EBNA2. The DNA probe (lane 1) was either incubated with in
vitro generated RBPJκ alone (“IVT RBPJκ”, lane 2), with IVT-RBPJκ plus unmethylated E. coli-EBNA2 alone (“E. coli E2 + jκ”, lane 3) or remethylated E. coli-EBNA2 (“Rem. E2”)
together with in vitro synthesised RBPJκ (lane 4). The indicated combinations of E. coli-EBNA2, remethylated EBNA2 or Reticulocyte-based EBNA2 (”Retic E2”) were tested with IVT-
RBPJκ and control-antibody (“Co AB”, lanes 6 and 7), EBNA2-speciﬁc R3 antibody (“R3”, lanes 8 and 9), sDMA-speciﬁc antibody (“sDMA”, lanes 10 and 11) or the aDMA-speciﬁc
antibody (“aDMA”, lanes 12 and 13). The shifted and supershifted EBNA2-containing complexes are indicated. (D) aDMAmodiﬁcation of EBNA2 by in vitromethylation. EBNA2 was
synthesised in vitro in the E. coli-based RTS 500 system (Roche). This unmethylated E. coli-EBNA2 was then pre-incubated with unprogrammed reticulocyte lysate. The left lane
contains reticulocyte-derived EBNA2 (“IVT-EBNA2 Retic. Lysate”) and the adjacent lane features E. coli-synthesised EBNA2 (“IVT-EBNA2 E. coli lysate”) as detected by the EBNA2-
speciﬁc R3 antibody. The next lane contains unmethylated E. coli-EBNA2 (“IVT-EBNA2 E. coli lysate”), and the rightmost lane contains E. coli-EBNA2 remethylated with the
reticulocyte lysate (“IVT-EBNA2 E. coli-remethylated”). In these two lanes, EBNA2 was stained using the aDMA-speciﬁc antibody 6F12.
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aDMA speciﬁc antibody detected high levels of EBNA2 binding
consistent with the presence of aDMA-EBNA2 in promoter-bound
complexes (Fig. 8E). In contrast, the sDMA speciﬁc antibody detectedsigniﬁcantly less binding of sDMA-modiﬁed EBNA2 to the promoter.
Similar results demonstrating comparatively less association of
sDMA-modiﬁed EBNA2 with promoter sequences were obtained
using LMP1 and LMP2A promoter primers, with the peak of EBNA2
Fig. 7. Inhibition of EBNA2 methylation reduces LMP1 expression. B95.8 cells were
untreated (“−“) or treated (“+”) with the methylation inhibitor AdOx and analysed by
Western blot for the expression of EBNA2, LMP1, aDMA-EBNA2. Levels of EBNA2
(“EBNA2”, top panel), LMP1, aDMA-modiﬁed EBNA2 and β-actin as loading control
were determined using the antibodies R3, S12, 6F12 and AC15 (Sigma), respectively.
306 H. Gross et al. / Virology 397 (2010) 299–310binding detected by the primer sets encompassing one or more of
the RBPJκ sites (Figs. 8F–I). Control experiments conﬁrmed that
both aDMA and sDMA-speciﬁc antibodies were able to precipitate
equivalent amounts of EBNA2 protein from cross-linked chromatin
under ChIP conditions (supplemental Figure S4B), indicating that
the reduced signal obtained in the real-time PCR analysis reﬂects
a decreased association of sDMA-EBNA2 with promoter DNA.
These data therefore indicate that aDMA-modiﬁed EBNA2 is likely
to represent the predominant form of EBNA2 found at target
promoters in vivo.
Discussion
Here, we provide the ﬁrst demonstration of aDMA-methylation as
a novel modiﬁcation of EBNA2. In addition, essentially all EBNA2
molecules in the cell are converted into methylated forms and
citrulline-containing EBNA2 was not detectable. Our data show that
methylation inﬂuences the interaction of EBNA2 with RBPJκ and
implicate methylation in the regulation of the activity of this
oncoprotein. It has been demonstrated that histones undergo various
secondary modiﬁcations including Arginine methylation (Jenuwein
and Allis, 2001). In addition to methylation at Lysine residue 7,
histone H3 may be methylated at Arginine 8 by either PRMT5 or
PRMT1. The latter modiﬁcation was shown to activate transcription,
while methylation by PRMT5 inactivated transcription (Pal et al., 2004
and references therein). We assume that PRMT1 generates aDMA-
modiﬁed histone H3, while PRMT5 produces sDMA-histone H3. No
clear picture has emerged for methylation of transcription factors. For
example, aDMA-STAT1 generated by PRMT1 (Mowen et al., 2001) as
well as sDMA-IL-2 generated by PRMT5 (Richard, Morel, and Cleroux,
2005) were both activating. We have not formally shown that EBNA2
is methylated by PRMT1 but it is likely that either PRMT1 or another
type I methyltransferase is responsible for the generation of aDMA-
containing EBNA2. In our assays, we ﬁnd predominantly aDMA-
modiﬁed EBNA2 at promoters in vivo, indicating that type I
methyltransferases produce a positive effect on transcription in this
context.
The data obtained from our ChIP analyses indicated that less sDMA-
modiﬁed EBNA2 associated with three EBV target promoters in vivo,
compared to the signals obtained using the R3 or aDMA-speciﬁc
antibodies. These data indicate that the aDMA-modiﬁed form of EBNA2
preferentially associates with promoters in vivo. Nonetheless, these ChIP
experiments do detect some sDMA association with promoters in
contrast with the results of the gel shift experiments where the sDMA-
speciﬁc antibody was not able to supershift an EBNA2-RBPJκ DNA
complex at all. It is possible that the sDMA antibody epitope is occluded
in the EBNA2-RBPJκ-DNA complex formed in vitro, possibly by otherfactors present in the complex. The association of EBNA2 and/or RBPJκ
with the additional components of the transcriptionalmachinerypresent
at promoters in vivomay result in the release of these factors or induce a
conformational change in the complex that re-exposes the epitope. It is
also possible that aDMA-EBNA2 binds to RBPJκ directly while sDMA-
EBNA2 associates with other factors present at the promoters in vivo.
We have demonstrated previously that EBNA2 targets the survival
of motor neurons (SMN) protein via its RG-repeat modiﬁed by the
type II PRMT5 (Barth et al., 2003) and that co-expression of SMN
activates transcription by EBNA2 (Voss et al., 2001). However, a ChIP
analysis using antibodies against SMN did not yield a signal from the
LMP1 promoter although SMN was clearly precipitated (data not
shown). It is still unclear why the deletion of the RG-repeat reduces
transformation by EBNA2 while the expression of the viral oncogene
LMP1 is strongly up-regulated. One possibility is that the deletion of
the RG-repeat without insertion of a spacer to replace the deleted
amino acids results in an altered EBNA2 protein that is able to interact
with RBPJκ while the presence of the non-methylated RG-repeat
inhibits association with DNA-bound RBPJκ. This data is in line with
our ﬁnding that inhibition of EBNA2 methylation results in a decrease
of LMP1 protein synthesis.
Interestingly, although AdOx treatment reduced the level of
methylated EBNA2, it did not completely ablate it. It is unclear
whether EBNA2 undergoes demethylation (deimination) within its
RG-repeat as we saw no citrulline-containing EBNA2 with our
antibodies. Because the half-life of EBNA2 is very long (Grässer et
al., 1991), it is unlikely that proteolytic degradation of EBNA2 removes
“active” EBNA2 from the cell. However, DNA-bound aDMA-EBNA2
was phosphorylated, while the sDMA-EBNA2 was not. It is possible
that during mitosis, as shown by others (Yue et al., 2004), the DNA-
bound aDMA-EBNA2 is reversibly inactivated through phosphoryla-
tion at Ser243.
In summary, we show that EBNA2 contains both sDMA and aDMA-
residues and that methylation is required for DNA-binding by EBNA2,
with aDMA-modiﬁed EBNA2 preferentially associated with promoters
in vitro and in vivo. In addition, only aDMA-containing EBNA2 is
phosphorylated pointing at further functional differences between
these subspecies of EBNA2. Further studies will be necessary to
determine how differential methylation of EBNA2 regulates its
association with the components of the transcriptional machinery
and affects its biological activities.
Materials and methods
Generation of monoclonal antibodies (mAbs)
Lou/C rats or BALB/c mice were immunised with KLH-coupled
peptides corresponding to the Arginine–Glycine repeat of EBNA2 that
contained either non-methylated Arginines (NMA), symmetrically
(sDMA) or asymmetrically (aDMA) dimethylated Arginine residues or
a peptide containing citrulline instead of Arginine residues. The
peptides were based on the sequence NH2-C-GQSRGRGRGRGRGRGK
GKSRDK; the amino terminal, non-EBNA2-derived Cysteine residue
was added for covalent coupling to KLH or OVA. The screening was
carried out by ELISA with the peptides coupled to OVA using an
irrelevant peptide as a control (Barth et al., 2008). Positive clones
were then tested against the other peptides and only those that
reacted exclusively with their cognate peptide were established. KLH-
and OVA-coupled peptides were purchased from PSL, Heidelberg,
Germany. The rat mAb 8C12 (IgG2a) reacts with NMA-EBNA2, the
mouse mAb 13B10 (IgG2a) recognises sDMA-EBNA2, the mouse mAb
6F12 (IgG2b) binds to aDMA-EBNA2 and the rat antibody 4A6 (IgG1)
reacts with citrulline-containing EBNA2-derived peptide. The anti-
bodies R3, 1E6 and 6C8 were described previously (Kremmer et al.,
1995). R3 and 1E6 bind to a C-terminal epitope, 6C8 recognises the
WWP-repeat at aa 320 and destroys the EBNA2-RBPJκ-interaction
Fig. 8. Chromatin immunoprecipitation analysis. Location of the amplicons generated by the C promoter (A) or LMP1 promoter (B) or LMP2A promoter (C) real-time PCR primer sets.
Numbers refer to the start of the amplicons generated by the indicated primer sets relative to the transcription start sites. The RBPJκ and PU.1 binding sites are indicated by grey and
black boxes, respectively. The LMP1 promoter sequence has been inverted for simplicity and lies in the reverse orientation in the EBV genome. (D) Chromatin was
immunoprecipitated from Mutu I (I) or Mutu III cells (III) using the R3 rat mAb and analysed using Cp-speciﬁc primers. To allow comparison between antibodies and experiments
relative ChIP signals were calculated by expressing the percentage input signal relative to the Mutu III signal obtained with the furthest downstream primer set. Results show the
mean ± standard deviation for at least three independent experiments (n) carried out on at least two different batches of chromatin (c). (E) Chromatin immunoprecipitations
carried out using the aDMA EBNA2 speciﬁc (6F12, open bars) and sDMA EBNA2-speciﬁc (7D9, black bars) mouse mAbs, analysed using Cp speciﬁc primers. (F) Chromatin
immunoprecipitations carried out using the R3 rat mAb analysed using LMP1p-speciﬁc primers. (G) Chromatin immunoprecipitations carried out using the aDMA-EBNA2 and sDMA
EBNA2-speciﬁc mouse mAbs analysed using LMP1p speciﬁc primers. (H) Chromatin immunoprecipitations carried out using the R3 rat mAb analysed using LMP2Ap-speciﬁc
primers. (I) Chromatin immunoprecipitations carried out using the aDMA-EBNA2 and sDMA EBNA2-speciﬁc mouse mAbs analysed using LMP2Ap speciﬁc primers.
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308 H. Gross et al. / Virology 397 (2010) 299–310(Sauder et al., 1994). S12 binds to LMP1 (Mann et al., 1985), the
monoclonal antibody 3F10 (Roche, Penzberg, Germany) binds to the
HA-tag. Mouse AC-15 anti β-actin was from Sigma (München,
Germany).
Dot blot assay
Approx. 0.1 μg each of the OVA-coupled peptides (see above)
dissolved in PBS was spotted onto a nitrocellulose membrane
(Whatman Protran®, Dassel, Germany). OVA with HA-peptide reac-
tive with the HA-speciﬁc antibody 3F10 served as an internal control.
The membrane strips containing the different peptide conjugates
were blocked for 30 min at 25 °C with 1% non-fat dried milk dissolved
in PBS, and then incubated with the different antibodies diluted 1:10
in the milk/PBS solution overnight. The bound antibodies were
visualised by the ECL®-method (GE Healthcare, München, Germany)
was carried out as described (Barth et al., 2003) using goat-anti-rat or
-anti-mouse-antibody coupled to horseradish peroxidase as second-
ary antibody.
Cell lines and tissue culture
HEK 293-T cells were cultured in DMEM medium (GIBCO),
supplemented with 10% FCS and antibiotics, non-adherent cell lines
were grown in RPMI 1640 medium (GIBCO), supplemented with 10%
FCS, Na-Pyruvate and antibiotics. The EBV-infected cell lines Raji,
B95.8, IB4 and P3HR1 as well as 293-T cells were previously described
(Barth et al., 2003; Grässer et al., 1993; Voss et al., 2001). Mutu I and
Mutu III cell lines were a kind gift from Prof. Martin Rowe,
Birmingham, UK (Sample et al., 1991). Mutu I does not express
EBNA2 while Raji, Mutu III and B95.8 contain EBNA2. P3HR1 contains
a non-transforming virus that has a deletion in the EBNA2 gene. The
metabolic labelling of B95.8 cells with H332PO4 (Hartmann,
Braunscheig, Germany) and the analysis of precipitated EBNA2 by
SDS-PAGE and autoradiography was carried out as described (Grässer
et al., 1992).
Transfections
For transient expression of EBNA2 proteins, 5×106 293-T cells
were transfected with 8 μg/10 cm dish of the pSG5-EBNA2-wt or
pSG5-EBNA2-ΔRG expression vectors (Barth et al., 2003) using
Nanofectin® (PAA, Cölbe, Germany). Western blotting by the ECL®-
method (GE Healthcare, München, Germany) was carried out as
described (Barth et al., 2003).
Preparation of native whole cell extract
Raji or B95.8 cells were treated for 72 h with the methylation
inhibitor AdOx (Sigma, München, Germany) at 20 μM. Lytic viral
replication was induced by treatment of the cells for 48 h with 32 pM
of the phorbol ester TPA (Barth et al., 2008) and cells were lysed for
30 min on ice in buffer 1 (PBS supplemented with 0.5% IGEPAL
(Sigma) and 0.15 M NaCl) containing protease inhibitors (Pepstatin,
2 μg/mL, PMSF 10 μM, Leupeptin 1 μg/mL, Aprotinin 1 μg/mL). The
lysate was centrifuged in a tabletop centrifuge at 15.000×g for
15 min, and the supernatant was used for further analysis.
Preparation of native nuclear extracts
Raji or B95.8 cells either treated with AdOx or TPA (see above)
were cultivated for 72 or 48 h, respectively. Nuclear cell extracts were
prepared in a buffer containing 20 mM HEPES pH 7.9, 420 mM NaCl,
1.5 mMMgCl2, and 2mMEDTA pH 8.5 (Dignam, Lebovitz, and Roeder,
1983). Gel shift analysis was carried out exactly as described (Zimber
Strobl et al., 1993).Immunoprecipitation
The rat monoclonal antibody (mAb) R3 (rat IgG2a) recognises a
C-terminal epitope of EBNA2 (Kremmer et al., 1995) and induces a
“supershift” in electrophoretic mobility shift assays (Zimber Strobl et
al., 1993) while the clone 6C8 (rat IgG2a) binds to the Trp-Trp-Pro
motif of EBNA2 and interferes with binding to RBPJκ (Sauder et al.,
1994). For immunoprecipitation and gel-shift analysis, appropriate
mouse or rat IgG isotype controls were used. For precipitation,
400 μL of mAb supernatant were coupled to 100 μL of settled
protein-G-sepharose (“PGS”, GE Healthcare, München, Germany) for
1 h at 4 °C under agitation, sedimented at 5.000 rpm in a tabletop
centrifuge and washed once with 1 mL of lysis buffer 1. For
precipitation experiments either 400 μg protein of native whole cell
extract or 100 μg protein of native nuclear extract was added and
incubated for 2 h at 4 °C under agitation, washed three times with
lysis buffer 2 (PBS with 0.5% IGEPAL and 0.5 M NaCl) and once with
lysis buffer 1. The pellet was resuspended in 2×SDS sample-buffer
and incubated for 10 min at RT or heated at 98 °C. For Western blot
analysis using the aDMA-speciﬁc antibody 6F12, cell extracts or
precipitated material was resuspended for up to 3 h in sample buffer
without β-mercaptoethanol at RT without heating. Peptide inhibition
of the aDMA-speciﬁc antibody in Western blot analysis was carried
out by incubating 300 μL of 6F12 tissue culture supernatant with
20 μg of peptide dissolved in 10 μL PBS for 1 h prior to addition of the
antibody solution to the Western blot. Inhibition of the sDMA-
speciﬁc antibodies in immunoprecipitation experiments, 300 μL of
13B10 antibody solution was bound for 2 h to protein G Sepharose
(PGS), then 20 μg peptide in 20 μL of PBS was added and incu-
bated for 18 h at 4 °C. The PGS was then washed and used for
immunoprecipitation.
Sucrose-gradient centrifugation
Native nuclear extract (200 µL) was loaded on a 5–40% sucrose-
gradient (10 mM HEPES pH 7.9, 5 mM Na3PO4, 5 mM KCl, 0.5 mM
MgCl2, 1 mM DTT) and centrifuged at 265.000×g for 6 h at 4 °C.
Typically, 17 fractions were collected (Grässer et al., 1991) and either
concentrated by ethanol-precipitation prior to Western blotting or
subjected directly to precipitation as outlined above.
Electrophoretic mobility shift assay
Preparation of native nuclear extracts and electrophoretic mobility
shift assay (EMSA) was carried out as described above (Sauder et al.,
1994; Zimber Strobl et al., 1993). The gels were documented using a
PhosphoImager® (Amersham). In vitro transcription–translation of
EBNA2 was performed using the TNT® Coupled Reticulocyte Lysate
System (Promega, Mannheim, Germany) as described (Barth et al.,
2003) following the instruction of the manufacturer. Typically, 50 μL
of the transcription–translation mix were programmed with 1 μg of
vector DNA using T7 RNA polymerase. For in vitro generation of RBPJκ
in this system, we used the vector AJ247 (Maier et al., 2005) kindly
supplied by B. Kempkes, Helmholtz Zentrum München. To generate
non-methylated protein, EBNA2 was vitro transcribed–translated
using the E. coli-based “Rapid Translation System” (RTS 500®, Roche).
For this purpose, the coding region of EBNA2was PCR-ampliﬁed using
the primers EBNA2-5′Nde (5′-ccg gaa ttc cat atg cct aca ttc tat ctt gc)
and EBNA2-3′Sal (5′-gcg aat tcg tcg act tac tgg atg gag ggg cga g). The
PCR product was inserted as a NdeI-SalI fragment into the pIVEX2.3-
MCS vector supplied with the kit. This vector was then used to
program the “RTS 500” reaction. To methylate this E. coli-derived
EBNA2, 40 μL of the TRS 500 reaction mixture were incubated for 2 h
at 30°C with 25 μL of the reticulocyte lysate (see above) supplemented
with 2 μL of the 10× reaction buffer and S-Adenosyl-Methionine
(SAM) at 1.5 μM as a methyl group donor.
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Mutu cells were diluted to 5×105 cells/mL 24 h prior to chromatin
preparation. Cells were then resuspended at 1×107 cells/mL in fresh
media and chromatin prepared as described previously (Bark-Jones,
Webb, and West, 2006). For immunoprecipitations carried out with
the anti-sDMA EBNA2 (7D9) and anti-aDMA EBNA2 (6F12) mouse
antibodies, 50 μL of protein A/G sepharose beads (Sigma) were
precoated with 13.5 μg rabbit anti-mouse immunoglobulins (Dako)
overnight and then washed in immunoprecipitation dilution buffer
(Bark-Jones, Webb, and West, 2006). Beads were then further
incubated in 500 μL immunoprecipitation dilution buffer with
100 μL of either control, 7D9 or 6F12 hybridoma supernatant for 3 h
at 4 °C with rotation. For the R3 rat monoclonal antibody, 50 μL of
protein A/G sepharose beads were directly precoated by incubation
with 500 μL immunoprecipitation dilution buffer and 100 μL hybrid-
oma supernatant. Pre-coated beads were then washed and blocked by
incubation with 350 μg single-stranded sonicated salmon testes DNA
(Sigma) for 1 h at 4 °C with rotation and then re-washed. Chromatin
(105 μL) was diluted 10-fold in immunoprecipitation dilution buffer
and pre-cleared using 45 μL of pre-blocked protein A Sepharose slurry
at 4 °C for 1 h. Input control samples (40 μL) were then removed from
the supernatants and stored at -20 °C and the diluted chromatin
added to the antibody and salmon sperm coated beads and the
immune complexes collected by rotation at 4 °C overnight. Immune
complexes were then washed, and precipitated chromatin eluted and
proteinase K digested as described previously (Bark-Jones, Webb, and
West, 2006). DNA was puriﬁed using the QIAquick Gel extraction Kit
(Qiagen) and eluted in 110 μL sterile millipore water.
Real-time PCR
Quantitative PCR (Q-PCR) was performed using an Applied
Biosystems 7500 real time PCR machine. A series of dilutions of
input control DNA (1/4, 1/16, 1/64 and 1/256) from Mutu 1 and
Mutu III cells were used to create input standard curves for each
primer set. Results were expressed as percentage input control
following subtraction of the background signal obtained from control
immunoprecipitations carried out using isotype matched control
antibodies. Primers speciﬁc for the C promoter were described pre-
viously (Bark-Jones, Webb, and West, 2006). LMP1 promoter primers
ampliﬁed the region from -320 to -235 relative to the LMP1
transcription start site (left primer 5′ GCA GAT TAC ACT GCC GCT TC
3′, right primer 5′ GGC CAA GTG CAA CAG GAA 3′), the region
from +31 to +117 (left primer 5′ CCT GAG GAT GGA ACA CGA C 3′,
right primer 5′ AGA GGA GGA GAA GGA GAG CAA 3′) and the region
from+572 to +634 (left primer 5′ GGA GAT TCT CTG GCG ACT TG 3′,
right primer 5′ TGA GCA GGA TGA GGT CTA GGA 3′). LMP2A promoter
primers ampliﬁed the region from -272 to -209 relative to the LMP2A
transcription start site (left primer 5′ GAT AGC CTC GCG ACT CGT GGG
AA 3′, right primer 5′ AAT CTT CAC ACA CTG CTG CTG 3′), the region
from+148 to+228 (left primer 5′ CCA ATA TCC ATC TGC TTC TGG 3′,
right primer 5′ GGC TCT TCA TTA GAT TCA CGT TC 3′) and the region
from +379 to +470 (left primer 5′ CTC ATC TCA ACA CAT ATA TGA
AGA AGC 3′, right primer 5′ TTG ATG TGA CTT GTG ATG CAA T 3′).
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